EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with English-only global labels for a limited period of time. The global vial and carton labels are missing some important Canadian-specific information normally found on Health Canada approved labels (see the Information for healthcare professionals section).
RecallTracker